Ensacove: Dosage Form, Projected Sales, NCE-1 Date | Ensartinib

Ensacove

Ensacove is an oral kinase inhibitor for adults with ALK-positive, locally advanced or metastatic non-small cell lung cancer who haven’t previously received ALK-targeted therapy. It blocks ALK-driven signaling to help control tumor growth and delay disease progression.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Ensartinib
Innovator :

XCOVERY HOLDINGS INC
Approval Date :

18-Dec-24
NCE-1 Date :

18-Dec-28
NCE Date :

18-Dec-29
Dosage Form :

Oral Capsules
Strength :

25mg and 100mg
Therapeutic Category :

Anticancer
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

6
2026 :

14
2027 :

26
2028 :

36
2029 :

41
2030 :

43
2031 :

44

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Ensacove

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?